10x Genomics (TXG)
(Real Time Quote from BATS)
$17.30 USD
-0.19 (-1.09%)
Updated Jul 15, 2024 03:45 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TXG 17.30 -0.19(-1.09%)
Will TXG be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TXG based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TXG
10x Genomics (TXG) Surges 8.2%: Is This an Indication of Further Gains?
International Markets and 10x Genomics (TXG): A Deep Dive for Investors
TXG: What are Zacks experts saying now?
Zacks Private Portfolio Services
10x Genomics (TXG) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The Zacks Analyst Blog Highlights 10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp
3 Medical Products Stocks Set to Beat This Earnings Season
Other News for TXG
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024
Cathie Wood's ARK Investment buys 283K shares of 10x Genomics today
10x Genomics (TXG) Gets a Buy from Barclays
10x Genomics price target lowered by $12 at Barclays, here's why
Cathie Wood’s top and bottom performing ARKK holdings of H1